Clinical Trials Browser

Phase 2 × Breast Neoplasms × Gefitinib × Clear all

NCT00206492 2017-08-01

Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients

Phase 2 Terminated

Breast Neoplasms, Neoplasms

NCT00229697 2015-10-05

Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

Phase 2 Completed

Breast Neoplasms

NCT00077025 2014-07-16

Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00057941 2014-05-12

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

Phase 2 Completed

148 enrolled 7 charts

Breast Neoplasms

NCT00066378 2013-10-24

Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00082667 2013-02-25

Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast

Phase 2 Terminated

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT00049062 2013-02-21

Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00206414 2013-02-05

Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer

Phase 2 Terminated

Breast Neoplasms

NCT01732276 2012-12-03

The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00066339 2012-07-18

Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy

Phase 2 Completed

Breast Neoplasms

NCT00252811 2011-01-28

A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT00239343 2011-01-27

Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00080743 2009-08-06

Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00234403 2009-04-23

A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00247481 2009-04-23

ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00255463 2009-04-23

Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

Phase 2 Completed

Breast Neoplasms

NCT00637026 2009-04-23

Ph II Early BC Pre-Surgical Biologic Study

Phase 2 Completed

Breast Neoplasms

NCT00632723 2009-04-22

IRESSA™ (Gefitinib) in Breast Cancer Patients

Phase 2 Completed

Breast Neoplasms

NCT00428896 2008-07-21

A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00052169 2007-12-18

Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00319618 2007-12-18

Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms